Quanterix Corporation Q4 FY2025 earnings call

Everett Cunningham introduced his background and focus on understanding Quanterix's potential, aiming to evolve the company and establish open communication. Vandana Sriram discussed Q4 financials, product performance including Simoa, Spatial, consumables, and lab services. Mentioned 13 new assays launched in 2025, milestones for LucentAD complete like CMS approval and FDA submission. Also discussed synergy targets and progress towards breakeven profitability.

Fourth quarter total revenue was $43.9 million, an increase of 25% from the previous year and up 7% sequentially. Organic revenue was a decline of 22%. Simoa contributed $27 million, a 22% organic revenue decline. Spatial reported $17 million, down 23% year-over-year. Spatial revenues included $2.5 million from a terminated diagnostics development agreement. Consumables revenue was $23 million, up $3.8 million sequentially. Gross profit and margin for the fourth quarter was $20 million or 45.7%. Non-GAAP gross profit was $21.9 million and non-GAAP gross margins 50%.

Expect to report approximately $169 million to $174 million of revenue in 2026. GAAP gross margin range 45% to 49% and non-GAAP gross margin 49% to 53%. Anticipate achieving cash flow breakeven in the second half of 2026 and end the year with approximately $100 million of cash and no debt.

No specific risk discussion in the provided transcript

Q: Assessment of Quanterix' core businesses and near-term strategy adjustments, A: Everett talked about diversification of Spatial business, synergy targets, and focus on growth in Simoa and Spatial spaces.

Q: Pipeline and timing for Simoa ONE platform, A: Vandana mentioned regular assay launches, Everett discussed early access program for Simoa ONE and holistic review of product development.

Q: Prioritization of segments and investments in Alzheimer's diagnostics, A: Everett and Vandana talked about diagnostics opportunity, CMS approval, clinical utility studies, and cash plan for diagnostics investments.

Q: Accelerator Lab and lab services demand, A: Vandana talked about Q4 strength, Everett aimed for bigger pharma projects in Accelerator business